# GSK receives US FDA file acceptance for Jemperli

- Link: https://www.directorstalkinterviews.com/gsk-receives-us-fda-file-acceptance-for-jemperli/4121121066
- Published: 2023-06-06T07:43:47+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE:GSK) has announced the US Food and Drug Administration (FDA) accepted the
supplemental Biologics License Application (sBLA) for _Jemperli_ (dostarlimab) in
combination with chemotherapy for the treatment of adult patients with mismatch 
repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced
or recurrent endometrial cancer. If approved in this patient population, dostarlimab
plus chemotherapy could represent the first meaningful frontline treatment advancement
in decades for patients with primary advanced or recurrent endometrial cancer.

·   Submission accepted for Priority Review

·   Breakthrough Therapy designation granted for this potential indication

·   Application being reviewed under the FDA Project Orbis framework, which enables
concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United
Kingdom health authorities

The FDA granted Priority Review for this application and assigned a Prescription
Drug User Fee Act action date of 23 September 2023. Dostarlimab also was recently
granted Breakthrough Therapy designation for this potential new indication.

Under Project Orbis, an initiative from the FDA Oncology Center of Excellence that
provides a framework for concurrent submission and review of oncology products among
international partners, the dostarlimab sBLA will be reviewed by health authorities
in the US, Australia, Canada, Switzerland, Singapore and the United Kingdom.

> **Hesham Abdullah, Senior Vice President, Global Head of Oncology Development,
> GSK** **said:** “We are excited about this initial filing for this potential new
> indication for dostarlimab in the patient population that demonstrated the strongest
> treatment effect in the phase III RUBY trial. Long-term outcomes for patients 
> with primary advanced or recurrent endometrial cancer remain poor, and there is
> an urgent need to evolve the current standard of care, which is platinum-based
> chemotherapy. We look forward to working with the FDA and other health authorities
> as they review this application.”

Endometrial cancer is the most common gynaecologic cancer in developed countries,
^([[1]]) and there are about 60,000 new cases of endometrial cancer diagnosed every
year in the US. ^([[2]]) Approximately 15-20% of patients with endometrial cancer
will be diagnosed with advanced disease at the time of diagnosis. ^([[3]] [[4]])
An estimated 20-29% of all endometrial cancers are dMMR/MSI-H.^([[5]]) Chemotherapy
used alone is the current standard of care for primary advanced or recurrent endometrial
cancer, and many patients eventually experience disease progression.^([[6]])

Currently, in endometrial cancer, dostarlimab is approved in the US as monotherapy
in dMMR recurrent or advanced endometrial cancer that has progressed on or following
a prior platinum-containing regimen. If the sBLA is approved, dostarlimab could 
potentially be indicated earlier in treatment in combination with platinum-containing
chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial
cancer.

The sBLA is based on the prespecified interim analysis results from Part 1 of the
RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial. The trial met its primary endpoint 
of investigator-assessed progression-free survival (PFS), which demonstrated a statistically
significant and clinically meaningful benefit in patients treated with dostarlimab
plus carboplatin-paclitaxel in the dMMR/MSI-H population and in the overall population.
The data reflect a robust median duration of follow-up of ≥24.8 months. The safety
and tolerability analysis from RUBY showed a safety profile for dostarlimab and 
carboplatin-paclitaxel that was generally consistent with the known safety profiles
of the individual agents. These data (https://www.gsk.com/en-gb/media/press-releases/
phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-
to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer) were
presented at the European Society for Medical Oncology (ESMO) Virtual Plenary and
the Society of Gynecologic Oncology (SGO) Annual Meeting on 27 March 2023, and were
simultaneously published in _The New England Journal of Medicine_.

Part 1 of the RUBY trial continues to assess the dual-primary endpoint of overall
survival (OS) in the intent-to-treat (ITT) population. At the first interim analysis
in the ITT population, a clinically meaningful OS trend was observed among patients
receiving dostarlimab plus chemotherapy followed by dostarlimab. The OS analysis
was done at 33% maturity and statistical significance was not reached.

In April, the European Medicines Agency (EMA) validated (https://www.gsk.com/en-
gb/media/press-releases/european-medicines-agency-validates-marketing-authorisation-
application-for-jemperli-dostarlimab) GSK’s marketing authorisation application 
for dostarlimab plus chemotherapy for the treatment of dMMR/MSI-H primary advanced
or recurrent endometrial cancer.

Share on:
